Thus, our data support the observation that both CD4+ and CD8+ T cells are critical for efficient anti‐tumor immunity and are implicated in driving responses to immunotherapy (Ostroumov et al,2018; Aslan et al,2020). This evidence concerns the gene CD8A and neoplasm.